Challenges and Therapeutic Opportunities in the dMMR/MSI-H Colorectal Cancer Landscape.

ABSTRACT: About 5 to 15% of all colorectal cancers harbor mismatch repair deficient/microsatellite instability-high status (dMMR/MSI-H) that associates with high tumor mutation burden and increased immunogenicity. As a result, and in contrast to other colorectal cancer phenotypes, a significant subset of dMMR/MSI-H cancer patients strongly benefit from immunotherapy. Yet, a large proportion of these tumors remain unresponsive to any immuno-modulating treatment. For this reason, current efforts are focused on the characterization of resistance mechanisms and the identification of predictive biomarkers to guide therapeutic decision-making. Here, we provide an overview on the new advances related to the diagnosis and definition of dMMR/MSI-H status and focus on the distinct clinical, functional, and mo

SUBMITTER: Mulet-Margalef N 

PROVIDER: S-EPMC9954007 | biostudies-literature | 2023 Feb

REPOSITORIES: biostudies-literature